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Abstract
Background: Charcot-Marie-Tooth disease type 2 (CMT2) is a clinically and genetically heterogeneous group of inherited
axonal neuropathies. The aim of this study was to extensively investigate the mutational spectrum of CMT2 in a cohort of
patients of Han Chinese.
Methodology and Principal Findings: Genomic DNA from 36 unrelated Taiwanese CMT2 patients of Han Chinese descent
was screened for mutations in the coding regions of the MFN2, RAB7, TRPV4, GARS, NEFL, HSPB1, MPZ, GDAP1, HSPB8, DNM2,
AARS and YARS genes. Ten disparate mutations were identified in 14 patients (38.9% of the cohort), including p.N71Y in
AARS (2.8%), p.T164A in HSPB1 (2.8%), and p.[H256R]+[R282H] in GDAP1 (2.8%) in one patient each, three NEFL mutations in
six patients (16.7%) and four MFN2 mutations in five patients (13.9%). The following six mutations were novel: the individual
AARS, HSPB1 and GDAP1 mutations and c.475-1G.T, p.L233V and p.E744M mutations in MFN2. An in vitro splicing assay
revealed that the MFN2 c.475-1G.T mutation causes a 4 amino acid deletion (p.T159_Q162del). Despite an extensive
survey, the genetic causes of CMT2 remained elusive in the remaining 22 CMT2 patients (61.1%).
Conclusions and Significance: This study illustrates the spectrum of CMT2 mutations in a Taiwanese CMT2 cohort and
expands the number of CMT2-associated mutations. The relevance of the AARS and HSPB1 mutations in the pathogenesis of
CMT2 is further highlighted. Moreover, the frequency of the NEFL mutations in this study cohort was unexpectedly high.
Genetic testing for NEFL and MFN2 mutations should, therefore, be the first step in the molecular diagnosis of CMT2 in
ethnic Chinese.
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Introduction
Charcot-Marie-Tooth disease (CMT) is a clinically and
genetically heterogeneous group of inherited neuropathies sharing
common characteristics of progressive distal muscle weakness and
atrophy, foot deformities, distal sensory loss and depressed tendon
reflexes. They can be further categorized according to the
pathological or electrophysiological features, and the inherited
axonal neuropathy CMT type 2 (CMT2) is one of the subgroups
[1]. To date, mutations in as many as 14 different genes have been
implicated in CMT2, including KIF1B (CMT2A1) [2], MFN2
(CMT2A2) [3], RAB7 (CMT2B) [4], TRPV4 (CMT2C) [5], GARS
(CMT2D) [6], NEFL (CMT2E) [7], HSPB1 (CMT2F) [8], MPZ
(CMT2I/J) [9,10], GDAP1 (CMT2K) [11,12], HSPB8 (CMT2L)
[13,14], DNM2 (CMT2M) [15], AARS (CMT2N) [16], LAMIN A
(AR-CMT2A) [17] and MED25 (AR-CMT2B) [18]. Among them,
mutations in MFN2 have been found in approximately 11–24.2%
of CMT2 patients [19–22], whereas AARS and TRPV4 mutations
were only recently identified in limited CMT2 families [5,16], and
mutations in other genes were found in only a few patients.
Dominant-intermediate CMT (DI-CMT) is a rare form of
CMT with an autosomally dominant inheritance and intermediate
median nerve conduction velocities of 25–45 m/s. DI-CMT is
often misdiagnosed as CMT2, particularly if the diagnosis is based
on the examination of a single patient. Three causative genes for
DI-CMT have been identified: DNM2 (DI-CMTB) [23], YARS
(DI-CMTC) [24] and MPZ (DI-CMTD) [25].
A comprehensive knowledge of the mutational spectrum and
frequency of mutations within the CMT2 populations is
important. In a Taiwanese cohort of CMT2 of Han Chinese
origin, we extensively surveyed the mutations in the MFN2, RAB7,
TRPV4, GARS, NEFL, HSPB1, MPZ, GDAP1, HSPB8, DNM2,
AARS and YARS genes and report here the genetic and clinical
features of the mutations we investigated.
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Ethics Statement
The protocols for this study were approved by the Institutional
Review Board of the Taipei Veterans General Hospital. Written
informed consent was obtained from all of the participants.
Patients
Thirty-six CMT2 families of Han Chinese descent were
enrolled in this study. These families were selected from a
continuous series of 251 CMT pedigrees ascertained at the
neurology clinic of Taipei Veterans General Hospital, Taiwan by
standard electrophysiological evaluation. The diagnostic guidelines
for CMT2 described in the report of the 2nd Workshop of the
European CMT consortium were adopted [26]. Sensory involve-
ment was demonstrated in all the probands of the 36 CMT2
families by nerve conduction studies (NCS) to exclude hereditary
motor neuropathy (Table S1). The 17p11.2 duplication or
deletion, and mutations in PMP22, CX32 and its promoter, and
TTR had been excluded first by DNA analysis of the proband in
each family. The mode of inheritance was autosomal dominant in
20 familial cases, autosomal recessive in 7, and apparently
sporadic in 9 with no evidence of family history of peripheral
neuropathy (Table S1).
Mutation analysis
Genomic DNA was extracted from peripheral blood using
standard protocols. Mutational analyses of the MFN2, RAB7,
TRPV4, GARS, NEFL, HSPB1, MPZ, GDAP1, HSPB8, DNM2,
AARS and YARS genes were performed by PCR amplification
using intronic primers and direct DNA sequencing. The sense and
antisense strands of each amplicon were sequenced using the Big
Dye 3.1 di-deoxy terminator method (Applied Biosystems, Foster
City, CA) and the ABI Prism 3700 Genetic Analyzer (Applied
Biosystems). The amplicon sequences were compared against
published human gene sequences in the National Center for
Biotechnology Information (NCBI) database (http://www.ncbi.
nlm.nih.gov) to identify putative mutation. After validation of any
sequence variations in both the sense and antisense strands,
subcloning and subsequent sequencing of the amplicons were
further performed to confirm the sequence changes. Phylogenetic
conservation of the mutation sites was analyzed by aligning the
amino acid sequences from several species (retrieved from the
Entrez protein database in the NCBI database) using the ClustalX
2.012 program [27].
Analysis of abnormal splicing at MFN2 c.475-1G.T, the
splice acceptor mutation in MFN2 intron 5, using the
minigene method
We analyzed the splicing alteration of the MFN2 c.475-1G.T
mutation using an in vitro minigene method as previously described
[28]. In brief, we cloned the entire genomic DNA sequence of
human beta-globin (HBB) into pCDNA3.1 to construct the
backbone of the artificial minigene. We then independently
cloned a genomic DNA fragment that spanned from the 39 end of
intron 4 to the 59 end of intron 7 of human MFN2 that was
amplified from a patient with the MFN2 c.475-1G.T mutation or
a normal control (wild type) subject into the BsrGI site within
intron 2 of HBB. The minigene clones harboring either the wild
type or mutant splice acceptor sequences were selected and
verified by repeated sequencing. The minigenes were transfected
into 293T and HeLa cells using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA). Forty-eight hours after transfection, total RNA was
extracted and reverse-transcribed. The minigene transcripts were
amplified using primers corresponding to exons 5 and 7 of MFN2.
The amplicons were analyzed by electrophoresis and sequenced to
ascertain any abnormal splicing at MFN2 c.475-1G.T.
Haplotype analysis of the patients carrying the NEFL
p.E396K mutation
Seven individuals from 3 unrelated families (including 5 patients
and 2 unaffected individuals) carrying the NEFL p.E396K
mutation were haplotyped (Figure S1). A haplotype analysis was
performed to explore the possible founder effect of p.E396K using
seven polymorphic microsatellite markers flanking the NEFL gene:
D8S1739, D8S1771, D8S382, and D8S1839 are located telomer-
ic, and D8S1989, D8S481, and D8S1734 are centromeric to
NEFL. These seven markers cover a region of 4.6 Kosambi
centimorgans (KcM, sex-averaged). All of the information
regarding the primer sequences and allele marker sizes were
obtained from the National Center for Biotechnology Information
(NCBI) database.
Results
Ten disparate mutations were identified in 14 of the 36
unrelated patients (38.9% of our cohort), including p.N71Y in
AARS (2.8%), p.T164A in HSPB1 (2.8%), and a compound
heterozygous p.[H256R]+[R282H] mutation in GDAP1 (2.8%) in
one single patient each (Figure 1A, 2A, 3A). NEFL mutations were
identified in 6 patients (16.7%), including p.E396K, p.P8R and
p.P22S in three, two, and one patients each. In addition, MFN2
mutations were identified in 5 patients (13.9%), including
p.R364W in two and c.475-1G.T, p.L233V and p.E744M in
one patient each. The genetic, clinical and electrophysiological
features for the patients harboring these mutations are summa-
rized in Table 1. No mutations were found in RAB7, TRPV4,
GARS, MPZ, HSPB8, DNM2, or YARS genes. Despite an extensive
genetic survey, the genetic causes of CMT2 remain elusive in 22 of
the CMT2 patients (61.1%).
Six of the identified mutations were novel, including
p.[H256R]+[R282H] in GDAP1, p.T164A in HSP27, p.N71Y in
AARS, and c.475-1G.T, p.L233V and p.E744M in MFN2. Each
of these mutations occurs in an evolutionarily conserved region in
the genes and segregates with CMT phenotype within the
pedigrees (Figure 1B, 1C, 2B, 2C, 3B, 3C, Figure S2). None of
these mutations were found in the 1000 Genomes database
(http://browser.1000genomes.org) and 500 control subjects in our
population.
The minigene assay showed that the MFN2 c.475-1G.T
mutation, which affects the AG splice acceptor site, results in a
deletion of 12 nucleotides in the mRNA (c.475_486delACTGT-
GAACCAG), corresponding to the loss of 4 amino acid residues in
the protein (p.T159_Q162del; Figure 4). Haplotype analysis of the
three unrelated patients with the NEFL p.E396K mutation
revealed no common founder chromosome using seven polymor-
phic microsatellite markers flanking the NEFL gene, indicating
that their mutations did not arise from a common ancestor (Figure
S1 and Table S2).
The clinical features of the rare AARS, HSPB1, GDAP1, and
MFN2 c.475-1G.T mutations are briefly described here. Patient
1 (the proband II:1 in Figure 1C), who carries the AARS p.N71Y
mutation, presented at age 51 with a slowly progressive weakness
and atrophy of the legs that began at the age of 30. He had had
normal developmental milestones and finished the military service
at age 20. Physical examinations revealed marked atrophy and
mild weakness of the muscles in the legs and feet (scoring a 4/5 on
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weakness of the intrinsic hand muscles (score 4+/5). This patient
also had absent ankle reflexes, diminished other deep tendon
reflexes (DTR), and a mildly diminished sensation of all modalities
in the distal parts of the extremities without sensory complaints.
The proband’s mother (I:2), brother (II:4) and son (III:2) had
similar clinical manifestations, but their ages of onset varied widely
(45, 40 and 11 years, respectively). The proband’s two younger
sisters (II:3 and II:6) and niece (III:3) denied to have any
neurological symptoms; however, neurological examinations
uncovered mild atrophy, weakness in the intrinsic foot muscles
(score 4+/5) and generalized hyporeflexia in all of them.
Patient 2 (II:3 in Figure 2C) carrying the HSPB1 p.T164A
mutation, which is located in the a-crystallin domain of the heat
shock protein beta-1 (HspB1), has experienced a slowly progressive
weakness, muscle atrophy and sensory loss in the distal limbs since
the age of 20. He had severe sensory loss that resulted in
insensitivity to pain and temperature and subsequently suffered
repeated injuries with chronic ulcers on the feet since the age of
24. Physical examinations at age 34 revealed a severe atrophy and
weakness of the muscles in the legs and in the intrinsic muscles of
the hands and feet (score 0-1/5), absent knee and ankle reflexes
and decreased upper-limb DTRs, and a severely diminished
sensation of all modalities in the regions below the elbows and
knees. His father (I:1) had a similar clinical presentation at the age
of 29 with frequent trauma and burn injuries to the feet since age
32. His walking had been restricted to the use of a walker after age
60, and he became wheelchair-bound at age 66. He died of a
pneumonia at age 76. The proband’s eldest sister (II:1) has had
similar but milder clinical manifestations since the age of 32.
Physical examinations at age 40 revealed a marked atrophy and
weakness of the muscles in the legs and feet (score 223/5), mild
atrophy and weakness of the intrinsic hand muscles (score 424+/
5), absent ankle and knee reflexes and preserved DTRs of the
upper-limbs, and mildly diminished sensation of all modalities in
the distal parts of four limbs.
Patient 3 (Figure 3B), who carried the GDAP1 p.[H256R]
+[R282H] mutation, had a delayed onset of ambulation at 18
Figure 1. AARS p.N71 is evolutionarily conserved, and p.N71Y segregates with CMT2N disease. (A) Sense strand electropherogram of
patient and control genomic DNA, showing the heterozygous AARS mutation c.211A.T in the patient DNA, corresponding to the amino acid
substitution N71Y. (B) Evolutionarily conserved AARS p.N71 is shown using a protein sequence alignment of AlaRS orthologs. (C) The pedigree shows
segregation of the p.N71Y mutation (the amino acid change shown in red) with CMT2N. The arrow indicates the proband (Patient II-1). The squares
and circles represent males and females, and the close and open symbols represent affected and unaffected members. Family member II-5 was not
genotyped.
doi:10.1371/journal.pone.0029393.g001
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examinations at age 5 revealed a mild atrophy and weakness of the
intrinsic muscles of the feet (score 2/5), impaired dorsiflexion of
the feet (score 223/5), generalized areflexia, and mildly
diminished sensation of all modalities in regions distal to the
wrists and ankles, despite a lack of sensory complaints. She did not
have any relatives with similar presentations.
Patient 10 (Figure S2A), who carried the MFN2 c.475-1G.T
mutation, presented at age 20 with a slowly progressive weakness
and atrophy of the distal lower limbs with occasional numbness
since the age of 13. Physical examinations revealed pes cavus,
marked atrophy and mild weakness of the muscles in the legs and
feet (score 424+/5) but sparing the upper-limb muscles, absent
ankle reflexes and generalized decreases in other DTRs, and
mildly diminished sensation of all modalities in the distal parts of
all extremities without sensory complaints. He did not have any
features to suggest a brain involvement. His father and younger
brother had a similar clinical manifestation with an onset at
approximately 10 years of age.
Discussion
In this study, we conducted an extensive survey for the
mutations in the MFN2, RAB7, TRPV4, GARS, NEFL, HSPB1,
MPZ, GDAP1, HSPB8, DNM2, AARS and YARS genes in 36
unrelated patients with CMT2 and identified 10 different
mutations in 14 patients (10/36; 38.9% of our cohort). In the
study cohort, the frequency of NEFL mutations (6/36; 16.7%) was
unexpectedly high, and the frequency of MFN2 mutations (5/36;
13.9%) was consistent with other reports (11–24.2%) in previous
studies [19–22]. The high frequency of NEFL mutations was not
the result of a founder effect (Table S1). Moreover, the
pathogenicity of the three rare mutations in CMT2 (i.e., the
AARS p.N71Y, HSP27 p.T164A, and GDAP1 p.[H256R]+
[R282H]) was demonstrated because these mutations segregated
with CMT in the families, involved highly conserved amino acids,
and were absent on the 1000 control chromosomes. We also used
the minigene assay to demonstrate that the MFN2 splice acceptor
site mutation c.475-1G.T may cause abnormal mRNA splicing
and result in a 4-amino acid deletion (p.T159_Q162del). Since the
study cohort was selected from a consecutive series of 251 CMT
pedigrees and we did not find any NEFL or GDAP1 mutations
among the index patients (data not shown), the mutation
frequencies for CMT in our population were 2.4% (6/251) for
NEFL, 2.0% (5/251) for MFN2, and 0.4% (1/251) for each of
AARS, HSPB1 and GDAP1.
Patient 1 carries a rare mutation in the AARS gene, which codes
for alanyl-tRNA synthetase (AlaRS), an enzyme that is essential for
protein synthesis by catalyzing the aminoacylation of tRNA
Ala
molecules with alanine. This process loads the tRNA
Ala with
alanine. A single mutation in the helical domain of AlaRS
(p.R329H) was recently described in two families with autosomal
dominant axonal CMT (CMT2N) [16]. The AARS p.N71Y
mutation, which segregates with disease in the family, is located in
Figure 2. HSPB1 p.T164 is evolutionarily conserved and segregates with CMT2F in the family. (A) Sense strand electropherogram of
patient and control genomic DNA, showing the heterozygous HSPB1 mutation c.490A.G in the patients DNA, corresponding to the amino acid
substitution T164A. (B) Evolutionarily conserved HSPB1 p.T164 is shown using a protein sequence alignment of HspB1 orthologs. (C) The pedigree
depicts segregation of the T164A mutation (the amino acid change shown in red) with CMT2F.
doi:10.1371/journal.pone.0029393.g002
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aminoacylation reaction. Indeed, recent functional analyses (Dr.
Anthony Antonellis, personal communication, manuscript in
preparation) demonstrated that N71Y AlaRS severely impairs
enzyme activity in vitro and in vivo. The phenotype in our patients
with this AARS mutation was similar to that reported previously
with the AARS p.R329H mutation. All of the patients were
ambulatory and had pure axonal neuropathy with a variable age
of onset (ranging from 11–45 years of age). AlaRS is the third
aminoacyl-tRNA synthetase that has been found to be involved in
CMT. CMT can also result from defects in glycyl-tRNA
synthetase, tyrosyl-tRNA synthetase, or lysyl-tRNA synthetase,
although these are rare [6,24,29]. Why mutations in these
ubiquitously expressed genes result solely in neuropathy remains
unknown. This study helps confirm the involvement of AARS
mutations in CMT and further demonstrates the role of
aminoacyl-tRNA synthetase in its pathogenesis.
Patient 2 carries a rare, novel mutation in the HSPB1 gene,
which encodes the small heat shock protein HspB1, a member of
the chaperone family. Small heat shock proteins (sHSPs) play an
important role in cellular defense during stress by binding
misfolded or denatured proteins to protect them from irreversible
aggregation [30]. They are ubiquitously expressed and are
characterized by the presence of a conserved a-crystallin domain.
The a-crystallin domain is essential for dimerization and
oligomerization of HspB1 [31], which are required for properly
functioning of HspB1 [30]. Only a few HSPB1 mutations have
previously been identified in families with CMT2F and families
with distal hereditary motor neuropathy (HMN2B), and most of
them are located in the a-crystallin domain [8,32]. The HSPB1
p.T164A mutation in Patent 2 is also located in the a-crystallin
domain and may influence the HspB1 function. The definitive
patho-mechanisms of HSPB1 mutations remain elusive and can’t
be fully explained by alteration of chaperone function. One recent
in vitro study showed that HSPB1 R127W and S135F mutations
significantly increased the chaperone activity of HspB1, R136W
mutation increased the chaperone activity slightly, and T151L and
P182L mutations did not change the chaperone activity [33]. In
addition to chaperone function, HspB1 has also been implicated in
regulating apoptotic pathways [34], enhancing oxidative defense
[35], and modulating cytoskeleton dynamics [36]. The phenotypes
of the HSPB1 mutations that have been reported to date are
motor-predominant neuropathy either with or without mild
sensory involvement. However, Patient 2 had sensorimotor
polyneuropathy with a severe sensory loss that resulted in repeated
foot injuries. This feature broadens the clinical spectrum of HSPB1
neuropathy.
Patient 3 carries a rare, novel compound heterozygous
mutation in the GDAP1 gene, which encodes ganglioside-induced
differentiation-associated protein 1 (GDAP1). GDAP1 regulates
mitochondrial dynamics by inducing mitochondrial fission [37],
which helps regulate mitochondrial function by controlling
Figure 3. GDAP1 p.H256 and R282 are evolutionarily conserved, and the p.[H256R]+[R282H] mutations segregate with recessive
CMT2. (A) The GDAP1 compound heterozygous mutations c. [767A.G]+[c.845G.A], which putatively result in p.[H256R]+[R282H], are shown by
sequencing TA-subcloned PCR fragments. (B) The evolutionarily conservation of GDAP1 p.H256 and R282 is shown using a protein sequence
alignment of GDAP1 orthologs. (C) The pedigree shows segregation of the GDAP1 p.[H256R]+[R282H] mutation with autosomal recessive CMT.
doi:10.1371/journal.pone.0029393.g003
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been reported in patients with autosomal dominant axonal CMT
(CMT2K) [11], recessive demyelinating CMT (CMT4A) [11],
recessive intermediate CMT (CMTRIA) [38], and recessive
axonal CMT with vocal cord paresis [12]. The clinical
manifestations of Patient 3 were similar to those reported
previously in patients with GDAP1-related recessive axonal
CMT, who presented with severe sensorimotor polyneuropathy
and a disease onset under the age of 2. The GDAP1 p.
[H256R]+[R282H] mutations are located in the GST-C
(glutathione-S-transferases, C-terminal region) domain. Although
a previous study showed that GDAP1 did not have functional
GST activity [39], the GST domains are important in GDAP1
function, as many GDAP1 mutations that are linked to CMT
involve the GST domains [40].
Patient 10 carries a rare, novel MFN2 acceptor splice site
mutation, that alters the consensus acceptor splice site of intron
5 from AG to AT and affects MFN2 splicing and expression. In
vitro splicing assays are valuable for evaluating the influence of
splicing mutations. MFN2 c.1392+2T.C, a mutation that affects
the donor splice site of intron 13, was recently identified in a
family with severe CMT2 and fatal encephalopathy [28].
Functional analysis revealed that this splice site mutation might
lead to four aberrant mRNA transcripts, which are predicted to
result in two different truncating frameshift mutations with two
approximate 260-amino acid deletions, one mutation with a 15-
amino acid insertion and one mutation with a 4-amino acid
deletion [28]. The MFN2 c.475-1G.T, which is carried by
Patient 10, was found to cause a deletion of 4 amino acids
(p.T159_Q162del), and this may explain his relatively mild
polyneuropathy.
Haplotype analysis revealed that Patients 7, 8 and 9, each of
whom carry the NEFL p.E396K mutation, did not have a common
founder. This suggests that E396 is a hot-spot for this spontaneous
mutation in the NEFL gene. This is supported by the fact that the
NEFL p.E396K mutation has also been reported in German,
Korean and Japanese patients with CMT despite the relative
rarity of NEFL mutations [41–43]. R364 in the mitofusin 2 protein
may also be a hot-spot for MFN2 mutations. Patients 12 and 13
both carry the de novo MFN2 p.R364W mutation and both had
severe and early onset CMT2. Among various populations, more
than 12 patients carrying the MFN2 p.R364W or p.R364P
mutation have been reported to have severe early onset CMT2
[19–22], which is obviously disadvantageous for reproduction.
Methylation and deamination of cytosine within a CpG
dinucleotide, which results in transitions of cytosine to thymine
[44], may play an important role in the recurrent mutations of
NEFL p.E396K (c.1186G.A, which causes ggcGAG.ggcAAG),
MFN2 R364W (c.1090C.T, which causes CGG.TGG), and
MFN2 R364P (c.1091G.A, which causes CGG.TAG), as they
each occur at the cytosine residue of a CpG dinucleotide in the
sense or antisense strand.
Our survey of mutations previously implicated in CMT2
revealed that the genetic causes of the disease in approximately
60% of patients in our cohort remain unidentified. Although a few
additional, rare CMT2 genes have not been screened, these
genetically unassigned patients likely reflect additional genetic
heterogeneity within the CMT2 syndrome.
The limitation of this study is that we had difficulty recruiting
more family members of the CMT2 pedigrees with the novel
mutations, and most of these pedigrees are small for segregation
analysis to firmly support the pathogenic roles of these mutations.
However, the pathogenic role of these novel disease-causing
mutations are still implicated by the involvement of highly
conserved amino acids and their absence in 1000 control
chromosomes.
In conclusion, this study demonstrated the spectrum of CMT2
mutations in ethnic Chinese patients and expands the list of
CMT2-associated mutations. The importance of mutations in the
AARS and HSPB1 genes in the pathogenesis of axonal CMT was
further highlighted. The frequency of the NEFL mutation in our
population was unexpectedly high. Mutations in the NEFL and
MFN2 genes should be ascertained first during genetic testing for
CMT2 in patients of Chinese origin.
Table 1. Genetic and clinical information of patients with Charcot-Marie-Tooth diseases type 2 in this study.
Patient,
gender
Age
(yrs) Gene Nucleotide changes
Amino acid
change
Age of
onset (yrs) MNCV (m/s, mV) Family history CMTNS[45]
*1, M 51 AARS c.211A.T p.N71Y 30 m38.1, 6.3; u42.1, 6.5; pNR mother, siblings, son 9
*2, M 34 HSPB1 c.490A.G p.T164A 20 m32.1, 1.8; u34.5, 2.4; pNR father, sister 24
*3, F 5 GDAP1 c. [767A.G]+[845G.A] p.[H256R]+ [R282H] , 1 m35.1, 2.3; u48.1, 1.8; pNR no 13
4, F 26 NEFL c.23C.G p.P8R 10 m40.8, 0.5; u48.7, 0.6; pNR father, brother 16
5, M 47 NEFL c.23C.G p.P8R 10 m38.2, 1.5; u37.8, 1.0; pNR no 13
6, F 45 NEFL c.64C.T p.P22S 12 m33, 0.3; u41, 2.4; pNR father, siblings 12
7, F 43 NEFL c.1186G.A p.E396K 30 m47.9, 2.6; u43.5, 2.5; p33.5, 0.2 mother, siblings 16
8, M 27 NEFL c.1186G.A p.E396K , 1 m41.3, 1.6; u36.8, 5.6; pNR sister 10
9, F 60 NEFL c.1186G.A p.E396K 40 m40.3, 7.5; u43.3, 5.4; p27.1, 1.2 no 11
*10, M 20 MFN2 c.475-1G.T p.T159_Q162del 13 m56.5, 9.8; u60.7,12.6; p38.8, 3.4 father, brother 7
*11, M 41 MFN2 c.697C.G p.L233V 12 m65.3, 9; u57.6, 4.6; p44, 6.5 brother 3
12, M 6 MFN2 c.1090C.T p.R364W 2 m37.2, 4; u42.9, 4.5; pNR no 15
13, M 13 MFN2 c.1090C.T p.R364W 2 m40.2, 0.2; uNR; pNR no 23
*14, M 32 MFN2 c.2230_2231 delinsAT p.E744M 8 m49, 5.2; u48.2, 3.9; pNR father 13
Abbreviations: MNCV, motor nerve conduction velocity; yrs, years; m/s, meter per second; mV, millivolt; m, median nerve; u, ulnar nerve; p, peroneal nerve; NR, no
response; CMTNS, Charcot-Marie-Tooth Neuropathy Score [38].
*These patients have novel mutations.
doi:10.1371/journal.pone.0029393.t001
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PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e29393Figure 4. The MFN2 c.475-1G.T splice acceptor site mutation resulting in a 4-amino acid deletion. (A) The genetic DNA
electropherograms of the MFN2 c.475-1G.T mutation and wild type MFN2. (B) The structure of the minigene comprising the MFN2 genomic
sequence from the 39 end of intron 4 to the 59 end of intron 7 cloned into intron 2 of the human beta-globulin (HBB) gene. The arrows depict the
sequences that correspond to the primers that were used in the expression studies. (C) RT-PCR amplification of the minigene constructs (expressed in
293T and HeLa cells) using primers that are specific for MFN2 exons 5 and 7 (E5F and E7R). The wild type construct (WT) is correctly spliced, whereas
the mutant construct (Mut) containing the MFN2 c.475-1G.T is aberrantly spliced, leading to a 12-bp cDNA fragment deletion. (D) The genomic
sequences and cDNA electropherograms of the MFN2 exon 5 and 6 junction. The wild type, mutant, and cryptic splice acceptor site generated in the
mutant allele are underlined. The MFN2 c.475-1G.T splice acceptor site mutation causes a 12-bp deletion in the cDNA (c.475_486delACTGTGAAC-
CAG) and putatively a deletion of 4 amino acids in the MFN2 protein (p.T159_Q162del).
doi:10.1371/journal.pone.0029393.g004
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Figure S1 Three unrelated CMT2E pedigrees carrying
the NEFL E396K mutation. Patients 7 (A), 8 (B) and 9 (C) are
indicated with arrows. Asterisks (*) depicting the individuals who
received genetic screening of NEFL and haplotype analysis.
(DOC)
Figure S2 Three CMT2A pedigrees carrying novel
MFN2 mutations at phylogenetically conserved sites.
The novel MFN2 mutations in the pedigrees of Patients 10 (A), 11
(B) and 14 (C) are located in the phylogenetically conserved
regions. Shown are the electropherogams, pedigrees and nucleo-
tide sequence alignments of MFN2 orthologs, or protein sequence
alignments of mitofusin 2 orthologs.
(DOC)
Table S1 The mode of inheritance and electrophysiological
features of the 36 unrelated patients with Charcot-Marie-Tooth
disease type 2.
(DOCX)
Table S2 The haplotypes linked to the NEFL p.E396K mutation
in the three unrelated CMT2E patients.
(DOC)
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